mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say https:// arstechnica.com/health/2026/08 /mrna-cancer-vaccine-succeeded-in-phase-3-melanoma-trial-moderna-and-merck-say/
mastodon:infosec-exchange 34d ago
Moderna and Merck announced a successful clinical trial by August 21, 2026, for a personalized mRNA cancer vaccine paired with Merck's immunotherapy drug to treat melanoma. The breakthrough combines a customized vaccine designed to target specific cancer cells with immunotherapy.
Merck and Moderna announced on August 19, 2026, that their mRNA-based melanoma vaccine met its goals in a large clinical trial. The development represents significant progress in cancer immunotherapy and offers potential new treatment options for skin cancer patients.
We're proud to call Merck one of our partners! com/pharmalot/20...
Merck and Moderna announced on August 19, 2026, that their personalized mRNA cancer vaccine intismeran autogene, combined with Merck's immunotherapy Keytruda, significantly reduced melanoma recurrence in late-stage trials. Stock prices for both companies surged on the breakthrough.
Moderna and Merck announced a major cancer vaccine breakthrough by August 29, 2026, ending a century of unsuccessful attempts. U.S. regulatory approval could arrive as soon as 2027.
Moderna and Merck announced on August 19 that their mRNA-based cancer vaccine significantly extended disease-free survival in melanoma patients compared to Keytruda alone in a late-stage trial. Moderna's stock surged 100% following the announcement.
Moderna and Merck announced on August 19-21, 2026, that a personalized mRNA cancer vaccine combined with the drug Keytruda significantly reduced the risk of melanoma recurrence and spread in high-risk patients during late-stage trials, marking a major breakthrough in therapeutic cancer vaccines.
Incoherent mix: projectile strike in Strait of Hormuz with crew death and oil price rise; UN report on Gaza cropland destruction (3% usable); unrelated social media posts about website design and AI code testing.
On August 19–20, 2026, pharmaceutical giants Merck and Moderna announced that an experimental mRNA vaccine treatment demonstrated promise in preventing melanoma recurrence in high-risk patients, sending stock prices soaring. The companies reported positive signals but had not yet published detailed trial data.
On September 2-3, 2026, semiconductor industry leaders including SEMI CEO Ajit Manocha and executives from GPTC and Scientech Corporation discussed memory chip prices, the ongoing semiconductor supercycle, and surging demand for advanced packaging technology.
Pharmalot.. Pharmalittle..
137) en melanoma de alto riesgo tras cirugía; preparan solicitud de aprobación.
Cluster contains unrelated fragments: Trump administration spending on White House renovations and tariff policy; Alaska flood alerts; religious studies post; and AI labor market research. No single story connects these reports.
Unrelated posts linking to YouTube videos on China, bridges, music, and other random topics. No coherent news story; scattered entertainment and information sharing.
Cluster contains only YouTube video links and one-line social media posts with minimal context. No coherent narrative emerges from the fragments.